Arcus Biosciences Operating Income 2017-2022 | RCUS

Arcus Biosciences operating income from 2017 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Arcus Biosciences Annual Operating Income
(Millions of US $)
2021 $54
2020 $-124
2019 $-89
2018 $-55
2017 $-53
2016 $-18
Arcus Biosciences Quarterly Operating Income
(Millions of US $)
2022-03-31 $-67
2021-12-31 $281
2021-09-30 $-78
2021-06-30 $-76
2021-03-31 $-73
2020-12-31 $-52
2020-09-30 $2
2020-06-30 $-45
2020-03-31 $-28
2019-12-31 $-18
2019-09-30 $-23
2019-06-30 $-29
2019-03-31 $-19
2018-12-31 $-13
2018-09-30 $-12
2018-06-30 $-16
2018-03-31 $-13
2017-12-31 $-13
2017-09-30 $-23
2017-06-30 $-10
2017-03-31 $-7
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.792B $0.383B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.407B 10.06
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.180B 16.07
Biohaven Pharmaceutical Holding (BHVN) United States $10.170B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.223B 0.00
Emergent Biosolutions (EBS) United States $1.625B 6.95
Myovant Sciences (MYOV) United Kingdom $1.313B 0.00
Zymeworks (ZYME) Canada $0.365B 0.00
Gelesis Holdings (GLS) United States $0.122B 0.00
Ambrx Biopharma (AMAM) United States $0.110B 0.00
Enzo Biochem (ENZ) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00